Birinapant

比利那潘

Report date: 2025/07/29 20:00:11
NME

Base Information

Drug NameBirinapant
Drug Alias NameBirinapantum比瑞那帕TL-32711NSC-756502IGM-9427
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActioncIAP1/cIAP2 inhibitorsApoptosis stimulants
TargetscIAP1/cIAP2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesFallopian Tube Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrinceton University
China Registration ClassN/A

Develop Information

Active CompaniesIgm Biosciences IncNational Cancer Institute
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Medivir ABRoswell Park Cancer Institute +[4] 
Active IndicationsSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesFallopian Tube Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG